Overview

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Status:
Completed

Trial end date:
2015-10-03

Target enrollment:

Participant gender:

Summary

A single oral dose study in subjects with hepatic impairment and healthy control subjects. Subjects will stay at the clinical facility where interval blood samplings will be obtained and examined for drug effect.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb
ViiV Healthcare

Collaborator:

GlaxoSmithKline

Treatments:

Fostemsavir